Unclaimed Scholar Profile
Are you Graham Lawrence Cohen? This profile has been curated from verified academic registries. Claim your profile to edit affiliations, manage works, and access your dashboard.
Verified ScholarVerified at Life Groenkloof HospitalASIDASID-9991-6234-3163 orcid.org/0009-0001-4263-2693
Graham Lawrence Cohen
Faculty researcher at Life Groenkloof Hospital (ZA), specializing in Physical Sciences & Engineering. [Discipline: Physical Sciences & Engineering] [Scholar Type: Journal Research Scientist] [Career Tier: Distinguished Scholar] [Region: Southern Africa]
#Cancer Immunotherapy and Biomarkers#Cutaneous Melanoma Detection and Management#Melanoma and MAPK Pathways#Ovarian cancer diagnosis and treatment
Scholarly Profiles: Google Scholar
Citation Indices
Standard Scientometrics| All | Since 2021 | |
|---|---|---|
| Citations | 9,194 | 4,413 |
| h-index | 12 | 9 |
| i10-index | 12 | 8 |
Annual Citation Growth
Verified Citations / Year0
2020441
2021+40%618
2022+28%794
2023+33%1.1k
2024-8%971
2025-45%530
2026Scholarship Distribution & Proportions25 Articles • 0 Books & Monographs • 0 Applied Assignments
Continental Provenance:25% African Regional Citations (2,299) • 75% Global Research Impact (6,895)
25 Indexed WorksAuthentic Data
Co-Authors & Academic Collaborators
No verified co-authors registered on AfriJournal Index yet.
Browse African Scholars →Scientific Bibliography Ingestion Notice
AfriJournal Index synchronizes authentic African citations and scholarship from Crossref, OpenAlex, and verified institutional repositories. Due to external indexing latency, some historical works may not yet be ingested in this snapshot. If you are this scholar, claim this profile to link your ORCID and verify your complete bibliography.
Articles & Books (25)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Published in The Lancet•2019
DOI: 10.1016/s0140-6736(19)32591-7 Verified Peer-Reviewed
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Published in The Lancet•2019
DOI: 10.1016/s0140-6736(18)32409-7 Verified Peer-Reviewed
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Published in The Lancet•2018
DOI: 10.1016/s0140-6736(18)31257-1 Verified Peer-Reviewed
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Published in The Lancet Oncology•2021
DOI: 10.1016/s1470-2045(21)00152-2 Verified Peer-Reviewed
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
Published in Journal of Clinical Oncology•2008
DOI: 10.1200/jco.2008.17.3138 Verified Peer-Reviewed
Showing 1 – 5 of 25 publications
1 / 5